Agios Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
529900ONJHY8EOGYT555 - ISIN
US00847X1046 (AGIO )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. Read full profile
Fundamentals
- Net revenue
€34.86M - Gross margin
85.1% - EBIT
-€393.67M - EBIT margin
-1,129.1% - Net income
€554.49M - Net margin
1,590.4%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Scadden David | N/A |
|
|
|
|
| Goff Brian | Chief Executive Officer |
|
|
|
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Gilbert Cisneros | May 6, 2025 | $1.00K–$15.00K |
| Gilbert Cisneros | February 11, 2025 | $1.00K–$15.00K |
Earnings Calls
Earnings Calls
Latest earnings call: May 2, 2024 (Q1 2024)